Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 22 May 2007
Vol. 2007, Issue 387, p. tw180
[DOI: 10.1126/stke.3872007tw180]

EDITORS' CHOICE

Medicine Smart Drugs, Smarter Tumors

Paula A. Kiberstis

Science, AAAS, Washington, DC 20005, USA

A promising class of "smart" cancer drugs work by inhibiting specific tyrosine kinases linked to uncontrolled growth. Gefitinib and erlotinib, drugs that target the kinase activity of the epidermal growth factor receptor (EGFR), can be very effective when initially administered to lung cancer patients whose tumors contain activating mutations in the EGFR gene. Almost inevitably, however, these tumors develop resistance to the drugs and begin to regrow. Engelman et al. find that drug resistance in a subset of these tumors is caused by amplification of the MET oncogene, an event that in turn activates, via a different route, the same cellular signaling pathway originally activated by the mutant EGFR.

J. A. Engelman, K. Zajnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Jänne, MET Amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). [Abstract] [Full Text]

Citation: P. A. Kiberstis, Smart Drugs, Smarter Tumors. Sci. STKE 2007, tw180 (2007).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882